COVCOG: Immediate and long-term cognitive improvement after cognitive versus emotion management psychoeducation programs-a randomized trial in covid patients with neuropsychological difficulties

BackgroundCognitive difficulties are a frequent complaint in long COVID and persist for more than a year post- infection. There is a lack of evidence-based data on effective intervention strategies. Non-pharmacological intervention programs that are used with other neurological populations have not yet been the subject of controlled trials. COVCOG is a multicentric, randomized trial comparing cognitive intervention and a cognitive-behavioural counselling.Methods/designPatients with long covid are selected and recruited at least three months post-infection. Patients are randomised in a 1:1 ratio into the cognitive (neuropsychological psychoeducation) and affective (emotion management with cognitive-behavioural counselling) intervention arms. The inclusion of 130 patients is planned. The cognitive intervention includes psycho-educational modules on fatigue and sleep, attention and working memory, executive functions and long-term memory. The affective intervention includes modules on emotion recognition and communication, uncertainty management and behavioral activation. The main objective is to reduce cognitive complaints 2 months after the intervention. A Follow-up is also planned at 8 months.DiscussionGiven the long-term effects of Covid on cognition and the negative effects of cognitive impairment on quality of life and social participation, it is important to determine whether low-dose, non-pharmacological interventions can be effective. The trial will determine which of the usual types of intervention is the most effective.

Automated summary

Cognitive difficulties are common in long COVID and continue to persist for more than a year. Evidence-based intervention strategies are lacking. The COVCOG trial aims to compare cognitive intervention and cognitive-behavioural counselling to determine the most effective approach in reducing cognitive complaints in long COVID patients.